Evidence map›Paper›PMID 26931562›Full record

ArticleBMC cancer2016

Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.

Stratigoula Sakellariou, Paraskevi Fragkou, Georgia Levidou, Antonios N Gargalionis, Christina Piperi, Georgia Dalagiorgou, Christos Adamopoulos, Angelica Saetta, George Agrogiannis, Irini Theohari and 9 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Identification of HAGHL as a novel metabolic oncogene regulating human colorectal cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Stratigoula SakellariouFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. sakellarioustrat@yahoo.gr.
Paraskevi FragkouFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. evankekkos@hotmail.com.
Georgia LevidouFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. glevidou@yahoo.gr.
Antonios N GargalionisDepartment of Biological Chemistry, University of Athens, Medical School, Athens, Greece. agargalionis@yahoo.gr.
Christina PiperiDepartment of Biological Chemistry, University of Athens, Medical School, Athens, Greece. cpiperi@med.uoa.gr.
Georgia DalagiorgouDepartment of Biological Chemistry, University of Athens, Medical School, Athens, Greece. gdalagior@med.uoa.gr.
Christos AdamopoulosDepartment of Biological Chemistry, University of Athens, Medical School, Athens, Greece. chr.adamopoulos@gmail.com.
Angelica SaettaFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. asaetta@med.uoa.gr.
George AgrogiannisFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. agrojohn@med.uoa.gr.
Irini TheohariFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. theoirene@hotmail.com.
Stavros SougioultzisDepartment of Pathophysiology, "Laikon" General Hospital, University of Athens, Medical School, Athens, Greece. ssougiou@med.uoa.gr.
Panagiota TsioliFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. peggytsioli@gmail.com.
Ioannis KaravokyrosFirst Department of Surgery, "Laikon" General Hospital, University of Athens, Medical School, Athens, Greece. ikaravok@med.uoa.gr.
Nikolaos TsavarisDepartment of Pathophysiology, Oncology Unit, "Laikon" General Hospital, University of Athens, Medical School, Athens, Greece. tsavari1@otenet.gr.
Ioannis D KostakisSecond Department of Propedeutic Surgery, "Laiko" General Hospital, University of Athens, Medical School, Athens, Greece. ioannis.kostakis@gmail.com.
Adamantia Zizi-SerbetzoglouDepartment of Pathology, "Tzaneio" General Hospital, Piraeus, Greece. adserbet@yahoo.gr.
Gerasimos P VandorosDepartment of Pathology, "Agios Andreas" General Hospital, Patras, Greece. gpvandoros@gmail.com.
Efstratios PatsourisFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. epatsour@med.uoa.gr.
Penelope KorkolopoulouFirst Department of Pathology, "Laikon" General Hospital, University of Athens, Medical School, Mikras Asias 75, Goudi, 11527, Athens, Greece. pkorkol@med.uoa.gr.
National and Kapodistrian University of Athens · GRAgios Andreas Hospital · GRTzaneion General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced glycation end products (AGEs) and their receptor RAGE emerge as important pathogenic contributors in colorectal carcinogenesis. However, their relationship to the detoxification enzyme Glyoxalase (GLO)-I and Adiponectin receptors (AdipoR1, AdipoR2) in colorectal carcinoma (CRC) is currently understudied. In the present study, we investigated the expression levels of the above molecules in CRC compared to adjacent non-tumoral tissue and their potential correlation with clinicopathological characteristics and patients' survival.

methodsWe analyzed the immunohistochemical expression of AGE, RAGE, GLO-1, AdipoR1 and AdipoR2 in 133 primary CRC cases, focusing on GLO-I. The tumour MSI status was further assessed in mucinous carcinomas. Western immunoblotting was employed for validation of immunohistochemical data in normal and tumoral tissues as well in three CRC cell lines. An independent set of 55 patients was also used to validate the results of univariate survival analysis regarding GLO-I.

resultsCRC tissue showed higher intensity of both AGE and RAGE expression compared with normal colonic mucosa which was negative for GLO-I in most cases (78 %). Western immunoblotting confirmed AGE, RAGE and GLO-I overexpression in tumoral tissue. GLO-I expression was directly related to RAGE and inversely related to AGE immunolabeling. There was a trend towards higher expression of all markers (except for RAGE) in the subgroup of mucinous carcinomas which, although of borderline significance, seemed to be more prominent for AdipoR1 and AGE. Additionally, AGE, AdipoR1 and Adipo R2 expression was related to tumor grade, whereas GLO-1 and AdipoR1 to T-category. In survival analysis, AdipoR2 and GLO-I overexpression predicted shortened survival in the entire cohort and in early stage cases, an effect which for GLO-I was reproduced in the validation cohort. Moreover, GLO-I emerged as an independent prognosticator of adverse significance in the patients' cohort.

conclusionsWe herein provide novel evidence regarding the possible interactions between the components of AGE-RAGE axis, GLO-I and adiponectin receptors in CRC. AGE and AdipoR1 are possibly involved in colorectal carcinogenesis, whereas AdipoR2 and GLO-I emerged as novel independent prognostic biomarkers of adverse significance for patients with early disease stage. Further studies are warranted to extend our observations and investigate their potential therapeutic significance.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCell Line, TumorColorectal NeoplasmsFemaleGlycation End Products, AdvancedHumansImmunohistochemistryKaplan-Meier EstimateLactoylglutathione LyaseMaleMiddle AgedNeoplasm GradingNeoplasm StagingADIPOR1 protein, humanADIPOR2 protein, humanBiomarkers, TumorGlycation End Products, AdvancedLactoylglutathione LyaseReceptor for Advanced Glycation End ProductsReceptors, Adiponectin

Identifiers

PMID26931562
PMCPMC4774155
OpenAlexW2291025194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.